Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Polycystic Ovary Syndrome 3Neoplasms 2Obesity 1Leukemia, Myeloid, Acute 1Hyperandrogenism 1Heart Failure 1Critical Illness 1Cardiotoxicity 1Acute Kidney Injury 1

Interventions

Cytarabine 55Decitabine 33Azacitidine 30Idarubicin 22venetoclax 21fludarabine 16Cyclophosphamide 16Granulocyte Colony-Stimulating Factor 15Daunorubicin 12Mitoxantrone 9Etoposide 8Cladribine 8Busulfan 8Aclarubicin 8Homoharringtonine 7Filgrastim 7Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5aclacinomycins 4Tretinoin 4Sorafenib 4Radiotherapy 4Polymerase Chain Reaction 4Mycophenolic Acid 4Lenalidomide 4Gemtuzumab 4Cyclosporine 4Clofarabine 4Arsenic Trioxide 4sargramostim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Myeloid, Acute × Spironolactone × Clear all
NCT03867682 2023-08-04

Venetoclax and Lintuzumab-Ac225 in AML Patients

Actinium Pharmaceuticals

Phase 1/2 Unknown
38 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡